CO6841996A2 - Inhibidores de la actividad de las celulas t - Google Patents
Inhibidores de la actividad de las celulas tInfo
- Publication number
- CO6841996A2 CO6841996A2 CO13301377A CO13301377A CO6841996A2 CO 6841996 A2 CO6841996 A2 CO 6841996A2 CO 13301377 A CO13301377 A CO 13301377A CO 13301377 A CO13301377 A CO 13301377A CO 6841996 A2 CO6841996 A2 CO 6841996A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitors
- cell activity
- activity
- cell
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503282P | 2011-06-30 | 2011-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6841996A2 true CO6841996A2 (es) | 2014-01-20 |
Family
ID=47424568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13301377A CO6841996A2 (es) | 2011-06-30 | 2013-12-27 | Inhibidores de la actividad de las celulas t |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9834604B2 (es) |
| EP (2) | EP3357511B1 (es) |
| JP (4) | JP6157461B2 (es) |
| KR (1) | KR20140058532A (es) |
| CN (2) | CN103796681B (es) |
| AU (3) | AU2012275133B2 (es) |
| BR (1) | BR112013033661A2 (es) |
| CA (1) | CA2839462A1 (es) |
| CL (1) | CL2013003725A1 (es) |
| CO (1) | CO6841996A2 (es) |
| CR (1) | CR20130661A (es) |
| DK (2) | DK3357511T3 (es) |
| DO (1) | DOP2013000313A (es) |
| ES (2) | ES2810424T3 (es) |
| GT (1) | GT201300323A (es) |
| HK (1) | HK1258401A1 (es) |
| HR (1) | HRP20181786T1 (es) |
| HU (1) | HUE040455T2 (es) |
| LT (1) | LT2726101T (es) |
| MA (1) | MA35280B1 (es) |
| MX (1) | MX354922B (es) |
| MY (1) | MY180616A (es) |
| NI (1) | NI201300140A (es) |
| PE (1) | PE20141469A1 (es) |
| PL (2) | PL2726101T3 (es) |
| PT (2) | PT2726101T (es) |
| RS (1) | RS57996B1 (es) |
| RU (1) | RU2657440C2 (es) |
| SG (1) | SG10201604715VA (es) |
| SI (1) | SI2726101T1 (es) |
| TN (1) | TN2013000532A1 (es) |
| UA (1) | UA116191C2 (es) |
| WO (1) | WO2013003761A1 (es) |
| ZA (1) | ZA201309532B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103429737B (zh) | 2010-11-30 | 2020-07-14 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
| EP3357511B1 (en) * | 2011-06-30 | 2020-05-13 | Genzyme Corporation | Inhibitors of t-cell activation |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| CA2894511C (en) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| IL247715B (en) | 2014-04-07 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Antigen binding molecules that activate the immune system |
| EP3144388B1 (en) * | 2014-05-13 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirecting antigen-binding molecule for cells having immunosuppression function |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
| CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
| JP2018512856A (ja) | 2015-04-17 | 2018-05-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | 調整可能な親和性を有する免疫調節タンパク質 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| BR112018004965A2 (pt) * | 2015-09-14 | 2018-10-09 | Alpine Immune Sciences Inc | domínios de superfamìlia de imunoglobulina variante ajustàvel |
| AU2016350701B2 (en) | 2015-11-02 | 2021-08-19 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| BR112018011781A2 (pt) | 2015-12-14 | 2018-12-04 | Macrogenics Inc | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica |
| KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
| AU2016371639A1 (en) | 2015-12-16 | 2018-06-28 | Merck Sharp & Dohme Llc | Anti-LAG3 antibodies and antigen-binding fragments |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| JP2019516665A (ja) * | 2016-03-02 | 2019-06-20 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CA3020542A1 (en) * | 2016-04-11 | 2017-10-19 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
| EP3443000A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| EP3442999A2 (en) | 2016-04-15 | 2019-02-20 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
| KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| EP3458095A4 (en) | 2016-05-18 | 2019-11-27 | Albert Einstein College of Medicine | PD-L1 POLYPEPTIDE VARIANTS, T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USING SAME |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| EP3558339B1 (en) | 2016-12-22 | 2024-01-24 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
| MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
| CA3078517A1 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| JP7436372B2 (ja) * | 2017-11-29 | 2024-02-21 | ユーティアイ・リミテッド・パートナーシップ | 自己免疫性疾患を治療する方法 |
| CN108003238B (zh) * | 2017-11-30 | 2021-02-02 | 常州费洛斯药业科技有限公司 | 一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP3747456A4 (en) * | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| BR112020023195A2 (pt) * | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
| CA3157613A1 (en) * | 2019-11-20 | 2021-05-27 | Gi Cell, Inc. | Medium composition for culturing t cells and method for culturing t cells using same |
| KR20230009872A (ko) | 2020-05-12 | 2023-01-17 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| CN114805591A (zh) * | 2022-03-31 | 2022-07-29 | 浙江大学 | 靶向ctla-4及配体cd80或cd86的双特异性抗体、筛选方法、组合物及应用 |
| WO2024036287A1 (en) * | 2022-08-12 | 2024-02-15 | Abata Therapeutics, Inc. | Stable regulatory t cells and methods of production |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5149782A (en) | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| WO1998023741A1 (fr) | 1996-11-28 | 1998-06-04 | Institut Gustave Roussy | Mutants de la proteine lag-3, leur expression et utilisation |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004076488A1 (en) * | 2003-02-27 | 2004-09-10 | Theravision Gmbh | A molecule which binds cd80 and cd86 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| SI1897548T1 (sl) * | 2003-02-28 | 2013-12-31 | The Johns Hopkins University | Regulacija celic T |
| JP2007537753A (ja) * | 2004-05-17 | 2007-12-27 | ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 抗原でパルスされた、二重特異性抗体（ＢｉＡｂ）でコーティングされた樹状細胞の使用 |
| WO2006029219A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| JP4944032B2 (ja) * | 2004-09-13 | 2012-05-30 | ジェンザイム・コーポレーション | 多量体構築物 |
| PT1844337E (pt) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Compostos ligantes, compostos imunogénicos e peptidomiméticos |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| EP2171062A1 (en) * | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| WO2009100140A1 (en) * | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| EP2653543A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and Compositions |
| BRPI0908496A2 (pt) | 2008-02-20 | 2019-01-15 | Genzyme Corp | inibição de angiogênese |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| EP3357511B1 (en) | 2011-06-30 | 2020-05-13 | Genzyme Corporation | Inhibitors of t-cell activation |
-
2012
- 2012-06-29 EP EP18151718.6A patent/EP3357511B1/en active Active
- 2012-06-29 ES ES18151718T patent/ES2810424T3/es active Active
- 2012-06-29 CN CN201280042085.9A patent/CN103796681B/zh active Active
- 2012-06-29 CN CN201711283703.XA patent/CN107988156B/zh active Active
- 2012-06-29 SG SG10201604715VA patent/SG10201604715VA/en unknown
- 2012-06-29 EP EP12804528.3A patent/EP2726101B1/en active Active
- 2012-06-29 DK DK18151718.6T patent/DK3357511T3/da active
- 2012-06-29 MX MX2013015384A patent/MX354922B/es active IP Right Grant
- 2012-06-29 PT PT12804528T patent/PT2726101T/pt unknown
- 2012-06-29 DK DK12804528.3T patent/DK2726101T3/en active
- 2012-06-29 RU RU2014102956A patent/RU2657440C2/ru not_active IP Right Cessation
- 2012-06-29 MY MYPI2013004609A patent/MY180616A/en unknown
- 2012-06-29 HU HUE12804528A patent/HUE040455T2/hu unknown
- 2012-06-29 LT LTEP12804528.3T patent/LT2726101T/lt unknown
- 2012-06-29 JP JP2014519165A patent/JP6157461B2/ja active Active
- 2012-06-29 PL PL12804528T patent/PL2726101T3/pl unknown
- 2012-06-29 US US14/128,461 patent/US9834604B2/en active Active
- 2012-06-29 UA UAA201400833A patent/UA116191C2/uk unknown
- 2012-06-29 ES ES12804528.3T patent/ES2694749T3/es active Active
- 2012-06-29 PT PT181517186T patent/PT3357511T/pt unknown
- 2012-06-29 SI SI201231438T patent/SI2726101T1/sl unknown
- 2012-06-29 BR BR112013033661A patent/BR112013033661A2/pt not_active Application Discontinuation
- 2012-06-29 PE PE2013002910A patent/PE20141469A1/es active IP Right Grant
- 2012-06-29 RS RS20181350A patent/RS57996B1/sr unknown
- 2012-06-29 CA CA2839462A patent/CA2839462A1/en not_active Abandoned
- 2012-06-29 KR KR1020147002646A patent/KR20140058532A/ko not_active Application Discontinuation
- 2012-06-29 WO PCT/US2012/045017 patent/WO2013003761A1/en active Application Filing
- 2012-06-29 PL PL18151718T patent/PL3357511T3/pl unknown
- 2012-06-29 AU AU2012275133A patent/AU2012275133B2/en not_active Ceased
-
2013
- 2013-12-13 CR CR20130661A patent/CR20130661A/es unknown
- 2013-12-18 ZA ZA2013/09532A patent/ZA201309532B/en unknown
- 2013-12-19 NI NI201300140A patent/NI201300140A/es unknown
- 2013-12-26 TN TNP2013000532A patent/TN2013000532A1/fr unknown
- 2013-12-26 GT GT201300323A patent/GT201300323A/es unknown
- 2013-12-26 CL CL2013003725A patent/CL2013003725A1/es unknown
- 2013-12-26 DO DO2013000313A patent/DOP2013000313A/es unknown
- 2013-12-27 CO CO13301377A patent/CO6841996A2/es unknown
-
2014
- 2014-01-22 MA MA36702A patent/MA35280B1/fr unknown
-
2017
- 2017-03-08 JP JP2017043440A patent/JP6530436B2/ja active Active
- 2017-10-19 US US15/788,433 patent/US11028170B2/en active Active
- 2017-11-15 AU AU2017261541A patent/AU2017261541B2/en not_active Ceased
-
2018
- 2018-10-30 HR HRP20181786TT patent/HRP20181786T1/hr unknown
-
2019
- 2019-01-17 HK HK19100808.1A patent/HK1258401A1/zh unknown
- 2019-05-15 JP JP2019091790A patent/JP6826154B2/ja active Active
- 2019-09-09 AU AU2019226276A patent/AU2019226276B2/en not_active Expired - Fee Related
-
2021
- 2021-01-14 JP JP2021003877A patent/JP2021073216A/ja active Pending
- 2021-05-03 US US17/306,509 patent/US20210380686A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6841996A2 (es) | Inhibidores de la actividad de las celulas t | |
| CO6920291A2 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante | |
| SMT201700109B (it) | Inibitori di istone demetilasi | |
| SMT201600238B (it) | Inibitori di protein chinasi | |
| SMT201600108B (it) | Derivato di pirazochinolina come inibitori di pde9 | |
| CO7010824A2 (es) | Inhibidores de aplicación viral | |
| CO6940421A2 (es) | Inhibidores de neprilisina | |
| BR112013010099A2 (pt) | boronatos como inibidores de arginase | |
| CO6781518A2 (es) | Inhibidores de neprilisina | |
| CO6940411A2 (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| CO6920296A2 (es) | Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona | |
| DK2685986T3 (da) | Glucosylceramidsyntasehæmmer | |
| CO6870035A2 (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112013030095A2 (pt) | inibidores de atividade de lrrk2 cinase | |
| BR112014000445A2 (pt) | usos de inibidores de hsp90 marcados | |
| BR112014013850A2 (pt) | conjunto de prateleiras | |
| SMT201600001B (it) | Imidazopiridazine come inibitori di akt chinasi | |
| BR112014003774A2 (pt) | inibidores de dyrk1 e usos dos mesmos | |
| BR112014003878A2 (pt) | síntese de r-bifenilalaninol | |
| CO6900144A2 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| CO6900148A2 (es) | Inhibidores de la enzima activadora de nedd8 | |
| CO6791617A2 (es) | Combinaciones de compuestos activos | |
| UA23780S (uk) | Акустична система |